3 Reasons to Sell REGN and 1 Stock to Buy Instead
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.
3 Reasons LNW is Risky and 1 Stock to Buy Instead
Over the last six months, Light & Wonder shares have sunk to $104.34, producing a disappointing 7.4% loss - worse than the S&P 500’s 1.4% drop. This might have investors contemplating their next move.
3 Reasons to Avoid VSEC and 1 Stock to Buy Instead
What a time it’s been for VSE Corporation. In the past six months alone, the company’s stock price has increased by a massive 44%, reaching $120 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.
IT Services & Other Tech Stocks Q4 Recap: Benchmarking Amdocs (NASDAQ:DOX)
Looking back on it services & other tech stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amdocs (NASDAQ:DOX) and its peers.
Spotting Winners: Cintas (NASDAQ:CTAS) And Industrial & Environmental Services Stocks In Q4
Looking back on industrial & environmental services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Cintas (NASDAQ:CTAS) and its peers.
Spotting Winners: UFP Industries (NASDAQ:UFPI) And Building Materials Stocks In Q4
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at UFP Industries (NASDAQ:UFPI) and the best and worst performers in the building materials industry.
3 Reasons DM is Risky and 1 Stock to Buy Instead
What a brutal six months it’s been for Desktop Metal. The stock has dropped 46.3% and now trades at $2.42, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.
3 Reasons to Sell MYRG and 1 Stock to Buy Instead
MYR Group currently trades at $124.23 and has been a dream stock for shareholders. It’s returned 506% since March 2020, more than tripling the S&P 500’s 152% gain. The company has also beaten the index over the past six months as its stock price is up 24.4% thanks to its solid quarterly results.